 Mortality of Drug-resistant Tuberculosis in High-burden Count Comparison of Routine Drug Susceptibility Testing with Whole-g Sequencing Martina L. Reichmuth,^{a*} Kathrin Zürcher,^{a*} Marie Ballif,^a Chloé Loiseau,^{b,c} Sonia Borre Reihnhard,^{b,c} Veronika Skrivankova,^a Rico Hömke,^{d,e} Peter Sander,^{d,e} Anchalee Avihingsand G Abimiku,^g Olivier Marcy,^h Jimena Collantes,ⁱ E. Jane Carter,^{i,k} Robert J. Wilkinson,^{I,m,n} H Marcel Yotebieng,^{p,q} Robin Huebner,^r Lukas Fenner,^a Erik C. Böttger,^{d,e} Sebastien Gagneux Egger,^{a,s} on behalf of the International epidemiology Databases to Evaluate AIDS (IeDEA) *contributed equally a) Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland b) Swiss Tropical and Public Health Institute, Basel, Switzerland c) University of Basel, Basel, Switzerland d) Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland 	
 Comparison of Routine Drug Susceptibility Testing with Whole-generation Sequencing Martina L. Reichmuth,^{a*} Kathrin Zürcher,^{a*} Marie Ballif,^a Chloé Loiseau,^{b,c} Sonia Borre Reihnhard,^{b,c} Veronika Skrivankova,^a Rico Hömke,^{d,e} Peter Sander,^{d,e} Anchalee Avihingsand G Abimiku,^g Olivier Marcy,^h Jimena Collantes,ⁱ E. Jane Carter,^{j,k} Robert J. Wilkinson,^{l,m,n} H Marcel Yotebieng,^{p,q} Robin Huebner,^r Lukas Fenner,^a Erik C. Böttger,^{d,e} Sebastien Gagneux Egger,^{a,s} on behalf of the International epidemiology Databases to Evaluate AIDS (IeDEA) *contributed equally a) Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland b) Swiss Tropical and Public Health Institute, Basel, Switzerland c) University of Basel, Basel, Switzerland d) Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland 	tries:
 Sequencing Sequencing Martina L. Reichmuth,^{a*} Kathrin Zürcher,^{a*} Marie Ballif,^a Chloé Loiseau,^{b,c} Sonia Borre Reihnhard,^{b,c} Veronika Skrivankova,^a Rico Hömke,^{d,e} Peter Sander,^{d,e} Anchalee Avihingsand G Abimiku,^g Olivier Marcy,^h Jimena Collantes,ⁱ E. Jane Carter,^{i,k} Robert J. Wilkinson,^{l,m,n} H Marcel Yotebieng,^{p,q} Robin Huebner,^r Lukas Fenner,^a Erik C. Böttger,^{d,e} Sebastien Gagneux Egger,^{a,s} on behalf of the International epidemiology Databases to Evaluate AIDS (IeDEA) *contributed equally a) Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland b) Swiss Tropical and Public Health Institute, Basel, Switzerland c) University of Basel, Basel, Switzerland d) Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland 	
 Martina L. Reichmuth,^{a*} Kathrin Zürcher,^{a*} Marie Ballif,^a Chloé Loiseau,^{b,c} Sonia Borre Reihnhard,^{b,c} Veronika Skrivankova,^a Rico Hömke,^{d,e} Peter Sander,^{d,e} Anchalee Avihingsand G Abimiku,^g Olivier Marcy,^h Jimena Collantes,ⁱ E. Jane Carter,^{j,k} Robert J. Wilkinson,^{l,m,n} H Marcel Yotebieng,^{p,q} Robin Huebner,^r Lukas Fenner,^a Erik C. Böttger,^{d,e} Sebastien Gagneux Egger,^{a,s} on behalf of the International epidemiology Databases to Evaluate AIDS (IeDEA) *contributed equally a) Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland b) Swiss Tropical and Public Health Institute, Basel, Switzerland c) University of Basel, Basel, Switzerland d) Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland 	,01101110
 Martina L. Reichmuth,^{a*} Kathrin Zürcher,^{a*} Marie Ballif,^a Chloé Loiseau,^{b,c} Sonia Borre Reihnhard,^{b,c} Veronika Skrivankova,^a Rico Hömke,^{d,e} Peter Sander,^{d,e} Anchalee Avihingsand G Abimiku,^g Olivier Marcy,^h Jimena Collantes,ⁱ E. Jane Carter,^{j,k} Robert J. Wilkinson,^{l,m,n} H Marcel Yotebieng,^{p,q} Robin Huebner,^r Lukas Fenner,^a Erik C. Böttger,^{d,e} Sebastien Gagneux Egger,^{a,s} on behalf of the International epidemiology Databases to Evaluate AIDS (IeDEA) *contributed equally a) Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland b) Swiss Tropical and Public Health Institute, Basel, Switzerland c) University of Basel, Basel, Switzerland d) Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland 	
 Martina L. Reichmuth,^{a*} Kathrin Zürcher,^{a*} Marie Ballif,^a Chloé Loiseau,^{b,c} Sonia Borre Reihnhard,^{b,c} Veronika Skrivankova,^a Rico Hömke,^{d,e} Peter Sander,^{d,e} Anchalee Avihingsand G Abimiku,^g Olivier Marcy,^h Jimena Collantes,ⁱ E. Jane Carter,^{j,k} Robert J. Wilkinson,^{l,m,n} H Marcel Yotebieng,^{p,q} Robin Huebner,^r Lukas Fenner,^a Erik C. Böttger,^{d,e} Sebastien Gagneux Egger,^{a,s} on behalf of the International epidemiology Databases to Evaluate AIDS (IeDEA) *contributed equally a) Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland b) Swiss Tropical and Public Health Institute, Basel, Switzerland c) University of Basel, Basel, Switzerland d) Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland 	
 Reihnhard,^{b,c} Veronika Skrivankova,^a Rico Hömke,^{d,e} Peter Sander,^{d,e} Anchalee Avihingsand G Abimiku,^g Olivier Marcy,^h Jimena Collantes,ⁱ E. Jane Carter,^{j,k} Robert J. Wilkinson,^{I,m,n} H Marcel Yotebieng,^{p,q} Robin Huebner,^r Lukas Fenner,^a Erik C. Böttger,^{d,e} Sebastien Gagneux Egger,^{a,s} on behalf of the International epidemiology Databases to Evaluate AIDS (IeDEA) *contributed equally a) Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland b) Swiss Tropical and Public Health Institute, Basel, Switzerland c) University of Basel, Basel, Switzerland d) Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland 	IL b.C. Miriam
 G Abimiku,^g Olivier Marcy,^h Jimena Collantes,ⁱ E. Jane Carter,^{j,k} Robert J. Wilkinson,^{I,m,n} H Marcel Yotebieng,^{p,q} Robin Huebner,^r Lukas Fenner,^a Erik C. Böttger,^{d,e} Sebastien Gagneux Egger,^{a,s} on behalf of the International epidemiology Databases to Evaluate AIDS (IeDEA) *contributed equally a) Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland b) Swiss Tropical and Public Health Institute, Basel, Switzerland c) University of Basel, Basel, Switzerland d) Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland 	
 Marcel Yotebieng,^{p,q} Robin Huebner,^r Lukas Fenner,^a Erik C. Böttger,^{d,e} Sebastien Gagneux Egger,^{a,s} on behalf of the International epidemiology Databases to Evaluate AIDS (IeDEA) *contributed equally a) Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland b) Swiss Tropical and Public Health Institute, Basel, Switzerland c) University of Basel, Basel, Switzerland d) Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland 	
 Egger,^{a,s} on behalf of the International epidemiology Databases to Evaluate AIDS (IeDEA) *contributed equally a) Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland b) Swiss Tropical and Public Health Institute, Basel, Switzerland c) University of Basel, Basel, Switzerland d) Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland 	
 *contributed equally *contributed equally a) Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland b) Swiss Tropical and Public Health Institute, Basel, Switzerland c) University of Basel, Basel, Switzerland d) Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland 	, mattinas
 *contributed equally a) Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland b) Swiss Tropical and Public Health Institute, Basel, Switzerland c) University of Basel, Basel, Switzerland d) Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland 	
 14 15 a) Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland 16 b) Swiss Tropical and Public Health Institute, Basel, Switzerland 17 c) University of Basel, Basel, Switzerland 18 d) Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland 	
 a) Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland b) Swiss Tropical and Public Health Institute, Basel, Switzerland c) University of Basel, Basel, Switzerland d) Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland 	
 b) Swiss Tropical and Public Health Institute, Basel, Switzerland c) University of Basel, Basel, Switzerland d) Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland 	
 17 c) University of Basel, Basel, Switzerland 18 d) Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland 	
 e) Swiss National Center for Mycobacteria, Zurich, Switzerland b) The LIN (Netherlande Australia Theiland (LIN) Descents Calleboration. Theil 	
 f) The HIV Netherlands Australia Thailand (HIV-NAT) Research Collaboration, Thai AIDS Research Centre and Tuberculosis research unit, Faculty of Medicine, Ch 	
22 University, Bangkok, Thailand	ulalongkom
 g) Institute of Human Virology Nigeria (IHVN), Abuja, Nigeria 	
 h) Centre de Prise en Charge de Recherche et de Formation, Yopougon, Abidjan, Cô 	
 i) Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Caye blana dia diana Darre 	etano
 Heredia, Lima, Peru j) Department of Medicine, Moi University School of Medicine, and Moi Teaching and 	Referral
28 Hospital, Eldoret, Kenya	ritoronia
29 k) Brown University School of Medicine, Providence, Rhode Island, USA	
 Wellcome Centre for Infectious Diseases Research in Africa, University of Cape To Depublic of Courth Africa 	own,
 Republic of South Africa m) Department of Infectious Diseases, Imperial College, London, UK 	
33 n) The Francis Crick Institute, London, UK	
 o) Institute for Infectious Disease and Molecular Medicine, University of Cape Town, I South Africa 	Republic of
p) National TB Lab, Kinshasa, Democratic Republic of the Congo (DRC)	
 q) Albert Einstein College of Medicine, New York, USA r) National Institutes of Allergy and Infectious Diseases, National Institutes of Health, 	Rothooda
 r) National Institutes of Allergy and Infectious Diseases, National Institutes of Health, MD, USA 	Dell'Iesua,
40 s) Centre for Infectious Disease Epidemiology and Research, Faculty of Health Scien	ces,
41 University of Cape Town, Cape Town, Republic of South Africa	
42 43	
44 Correspondence to : Marie Ballif, marie.ballif@ispm.unibe.ch, +41 31 631 35 18, Institute	of Social
•	51 000101
45 and Preventive Medicine, University Bern, Mittelstrasse 43, 3012 Bern, Switzerland	
46	
47 Word count: Abstract 350 words, main text 3260 words, 3 tables, 3 figures, 30	references,
48 supplementary materials.	
49 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide cl	inical practice
50	הוכמו אומכנונפ.

Abstract 51

52

53 Background: Drug-resistant Mycobacterium tuberculosis (Mtb) strains threaten tuberculosis (TB) control. We compared data on drug resistance obtained at clinics in seven high TB burden countries 54 55 during routine care with whole-genome sequencing (WGS) carried out centrally.

56 **Methods:** We collected pulmonary *Mtb* isolates and clinical data from adult TB patients in Africa, Latin 57 America, and Asia, stratified by HIV status and drug resistance, from 2013 to 2016. Participating sites 58 performed drug susceptibility testing (DST) locally, using routinely available methods. WGS was done 59 using Illumina HiSeg 2500 at laboratories in the USA and Switzerland. We used TBprofiler to analyse 60 the genomes. We used multivariable logistic regression adjusted for sex, age, HIV-status, history of TB,

61 sputum positivity, and *Mtb*-lineage to analyse mortality.

62 Findings: We included 582 TB patients. The median age was 32 years (interguartile range: 27-43 63 years), 225 (39%) were female, and 247 (42%) were HIV-positive. Based on WGS, 339 (58%) isolates 64 were pan-susceptible, 35 (6%) monoresistant, 146 (25%) multidrug-resistant, and 24 (4%) pre-/ extensively drug-resistant (pre-XDR/XDR-TB). The local DST results were discordant compared to 65 66 WGS results in 130/582 (22%) of patients. All testing methods identified isoniazid and rifampicin 67 resistance with relatively high agreement (kappa 0.69 for isoniazid and 0.88 rifampicin). Resistance to ethambutol, pyrazinamide, and second-line drugs was rarely tested locally. Of 576 patients with known 68 69 treatment, 86 (15%) patients received inadequate treatment according to WGS results and the World 70 Health Organization treatment guidelines. The analysis of mortality was based on 530 patients; 63 71 patients (12%) died and 77 patients (15%) received inadequate treatment. Mortality ranged from 6% in 72 patients with pan-susceptible Mtb (18/310) to 39% in patients with pre-XDR/XDR-TB (9/23). The 73 adjusted odds ratio for mortality was 4.82 (95% CI 2.43-9.44) for under-treatment and 0.52 (95% CI 74 0.03-2.73) for over-treatment.

75 Interpretation: In seven high-burden TB countries, we observed discrepancies between drug 76 resistance patterns from local DST and WGS, which resulted in inadequate treatment and higher 77 mortality. WGS can provide accurate and detailed drug resistance information, which is required to 78 improve the outcomes of drug-resistant TB in high burden settings. Our results support the WHO's call 79 for point-of-care tests based on WGS.

80

81 Keywords: Mycobacterium tuberculosis, tuberculosis (TB), drug resistance, drug-susceptibility testing 82 (DST), whole-genome sequencing (WGS), mortality

Introduction 84

85 Tuberculosis (TB) is caused by bacteria of the Mycobacterium tuberculosis complex (MTBC) and the leading cause of death by a single infectious agent worldwide. In 2018, ten million people were 86 87 estimated to have developed active TB, of whom 9% were people living with HIV (PLWH). In the same 88 year, around 1.5 million people died from TB, including 251,000 PLWH.¹ TB accounts for approximately 89 40% of HIV/AIDS-related adult deaths, and half of these remain undiagnosed.²

The emergence of drug-resistant Mycobacterium tuberculosis (Mtb) strains threatens TB control. In 90 91 2018, 3% of new TB cases worldwide were estimated to have multidrug-resistant TB (MDR-TB), and 92 18% of previously treated cases had MDR-TB.¹ PLWH are at greater risk of acquiring MDR-TB than 93 HIV-negative people.³ Further, treatment outcomes in PLWH co-infected with MDR-TB are worse than 94 among HIV-negative MDR-TB patients.³ Pre-extensively and extensively drug-resistant TB (pre-XDR-95 TB and XDR-TB) pose additional challenges for treatment and control of the disease.⁴ Strategies to 96 control and prevent drug-resistant TB include surveillance, drug susceptibility testing (DST), as well as 97 ensuring the completion of an adequate treatment regimen. However, the treatment of drug-resistant 98 TB is challenging particularly in low- and middle-income countries, due to limited access to DST and 99 effective second-line anti-TB drugs.¹ 100 The present study is part of a research program on drug-resistant TB of the International Epidemiology

101 Databases to Evaluate AIDS (IeDEA).⁵ In a previous analysis, we compared the results of drug susceptibility testing (DST) performed in high TB burden countries in sub-Saharan Africa, Asia and Latin 102 America with standardized phenotypic DST results obtained at the Swiss National Center for 103 104 Mycobacteria.⁶ We found that the accuracy of the DST performed at participating sites was moderate and that inadequate DST was associated with increased mortality. The Swiss reference laboratory 105 106 tested drug resistance to six drugs only: isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), 107 ethambutol (EMB), amikacin (AMK) and moxifloxacin (MFX). Therefore, other resistances could have 108 been missed, including to streptomycin (SM), kanamycin (KM), ethionamide (ETH), levofloxacin (LFX), 109 or newer drugs.

110 Whole-genome sequencing (WGS) can simultaneously provide information on resistance to first- and second-line drugs, for which drug-resistance-conferring mutations are known. WGS has the potential 111 to overcome many of the limitations of conventional DST with higher throughput.⁷ We and others 112 showed that drug susceptibility predicted from *Mtb* genomes correlates with phenotypic DST.^{8,9} The 113 114 World Health Organization (WHO) recommends WGS for drug resistance surveillance and is evaluating 115 sequencing technologies for routine DST.¹ Here, we compared the drug resistance patterns routinely obtained in seven high TB burden countries with the results from WGS, and examined the mortality 116 117 associated with discordant resistance profiles using WGS as the reference. 118

119 Methods

As described in detail elsewhere.⁶ we recruited patients from 2013 to 2016 at antiretroviral therapy 120 (ART) programmes and TB clinics serving the same catchment areas in Peru, Thailand, Côte d'Ivoire, 121 122 Democratic Republic of the Congo (DRC), Kenya, Nigeria, and South Africa. In South Africa, we used 123 strain collections held at the University of Cape Town. All patients had bacteriologically confirmed, or clinically diagnosed TB. We included adult patients (≥ 16 years) with pulmonary TB (PTB) or both PTB 124 125 and extrapulmonary TB. The recruitment of patients was stratified by HIV status and TB drug resistance 126 as defined at local clinics. We collected demographic and clinical characteristics of participants using a 127 standardised questionnaire. Mtb isolates were sub-cultured at the recruitment sites.

128 Drug resistance testing

Molecular or phenotypic DST was performed at local laboratories according to routine procedures. DNA 129 was extracted from *Mtb* isolates using standard protocols.¹⁰ Libraries were prepared using the Illumina 130 131 Nextera XT kit and sequenced on Illumina HiSeq 2500 at the Department of Biosystems Science and Engineering of the Swiss Federal Institute of Technology (ETHZ) in Basel and the Broad Institute in 132 133 Cambridge, MA, USA. Sequences had 101, 138, or 151 bp paired-end reads (Illumina, San Diego, CA, 134 USA). We screened one Mtb isolate per patient for anti-TB drug resistance mutations using the TBprofiler-v2.8.2 pipeline (https://github.com/jodyphelan/TBProfiler).^{7,11} The pipeline aligns reads to the 135 136 H37Rv reference genome using bowtie2-v2.3.5, BWA-v0.7.17 or minimap2-v2.16 and calls variants with SAMtools-v1.9.7,12-15 The variants were then compared to a drug-resistance database 137 (https://github.com/jodyphelan/tbdb; version of 30.01.2020). Single-nucleotide polymorphism (SNPs) 138 139 and insertion-deletion (Indels) responsible for resistance to 19 anti-TB drugs were identified.^{7,11,16} SM. para-aminosalicylic-acid (PAS), INH, PZA, cycloserine (CS), KM, ETH, EMB, AMK, RIF, capreomycin 140 141 (CAP), ofloxacin (OFX), ciprofloxacin (CIP), MFX, LFX, linezolid (LZD), bedaquiline (BDQ), clofazimine (CFZ), and delamanid (DLM). A coverage of 10 reads was needed to call a polymorphism. We 142 143 considered all drug resistance alleles with a variant frequency equal to or higher than 90%.

144 Definitions

- WHO defines monoresistance as resistance to one of the first-line drugs (INH-, PZA-, EMB-, and RIF).^{1,17} MDR-TB is defined as resistance to both INH and RIF. Pre-XDR-TB is defined as resistance against INH and RIF plus fluoroquinolones (FQLs) or one of the three second-line injectable (INJ) drugs (AMK, CAP, KM). Extensively drug-resistant TB (XDR-TB) is defined as drug-resistance against INH, RIF, FQLs and at least one of the three second-line INJ drugs.
- We compared the drug resistance profiles obtained at local sites to those obtained with WGS. Drug resistance profiles were defined as concordant or as discordant according to the resistance categories defined by WHO.¹ Discordant results were further categorized into discordant results potentially leading to under-treatment, or potentially leading to over-treatment (<u>Supplementary Table 1</u>).^{1,17} Discordances with no clear implications for treatment were defined as "other discordances". We assessed the adequacy of prescribed anti-TB treatment according to WHO guidelines (<u>Supplementary Table 1</u>).^{1,17} Effective drugs were defined as drugs to which *Mtb* strains had no drug resistance-conferring mutations

- 157 observed in whole-genome sequences (Supplementary Table 2). The prescription of less than three
- effective drugs was defined as under-treatment, except for patients with INH- or RIF-resistant Mtb. In 158
- 159 these patients, a regimen comprising less than four effective drugs was already considered as under-
- 160 treatment. Over-treatment included second-line drugs given to patients for whom first-line regimens
- 161 would have been adequate. Supplementary Table 3 shows the classification of regimens in detail.

Statistical methods 162

163 We used descriptive statistics to assess patient characteristics by levels of drug resistance based on 164 WGS. We calculated the agreement between the results of local and WGS drug resistance results using Cohen's Kappa statistic (in R package "psych").^{18,19} We compared the following drug resistance 165 categories: pan-susceptible TB, monoresistant TB (any monoresistance), MDR-TB, pre-XDR/XDR-TB, 166 167 any INH-resistant TB (including INH-monoresistant TB, MDR-TB and pre-XDR/XDR-TB), any RIF-168 resistant TB (including RIF-monoresistant TB, MDR-TB and pre-XDR/XDR-TB). We examined the 169 determinants of mortality in univariable and multivariable logistic regression models. Patients with missing data on treatment regimen, treatment outcome, ongoing treatment, and sputum microscopy, 170 171 respectively, were excluded from the analysis of mortality.

172 Four separate logistic regression models were performed to assess the impact on mortality: 1) the 173 impact of any drug resistance on mortality, 2) the impact of different types of drug resistance on 174 mortality, 3) the impact of discordant diagnoses on mortality, and 4) the impact of treatment adequacy 175 (according to WHO guidelines) on mortality. Logistic regression models were adjusted for sex, age, HIV-status, history of TB, sputum positivity, and *Mtb* lineage (Supplementary Table 4). All analyses 176 177 were performed in R v3.6.1 or Python v3.7.6.^{18,20} We conducted two sensitivity analyses. First, we repeated all logistic regression analyses after restricting the data to drug resistances that could be 178 179 diagnosed with the locally available tests. We thus excluded drug resistances that were missed due to 180 unavailable testing methods. Second, we examined the impact of different variant frequency cut-offs: > 181 0% and 100%.

182 **Ethics**

The Cantonal Ethics Committee in Bern, Switzerland, and local institutional review boards approved 183

the study. Written informed consent was obtained at all sites, except in South Africa, where consent 184 185 was not required for archived samples.

187 Results

188 Study population

Of the 634 patients included in our previous analysis,⁶ we failed to sequence 52 (8.2%) *Mtb* isolates for 189 190 technical reasons (Supplementary Figure 1). We thus included 582 TB patients, 406 (70%) from Africa, 191 83 (14%) from Asia, and 93 (16%) from Latin America. A total of 172 patients (30%) came from South 192 Africa, 94 (16%) from Côte d'Ivoire, 59 (10%) from the Democratic Republic of the Congo, 28 (5%) from Kenya, 53 (9%) from Nigeria, 93 (16%) from Peru, and 83 (14%) from Thailand (Table 1). The median 193 age was 32 years (interguartile range: 27-43 years), 225 (39%) were female, and 247 (42%) were HIV-194 195 positive. Six Mtb lineages were represented: 24 (4%) L1, 135 (23%) L2, 18 (3%) L3, 403 (69%) L4, one 196 (<1%) L5, and one (<1%) L6. Based on WGS, 339 (58%) isolates were pan-susceptible, 35 (6%) 197 monoresistant, including 24 (4%) RIF, 8 (1%) INH, 2 (<1%) PZA and 1 (<1%) EMB mono-resistant isolates. There were 146 (25%) MDR, and 24 (4%) pre-XDR/XDR isolates (Table 1; Figure 1). Among 198 the 24 patients with pre-XDR/XDR, 9/24 (38%) had resistance to FQLs, 6 (25%) to INJ, and 9 (38%) to 199 200 both.

201 Local results of DST

202 Local DST results were based on the molecular Xpert MTB/RIF test system, line probe assays (LPA), 203 and culture-based phenotypic tests or a combination of these methods (Table 2). Among the 582 Mtb 204 isolates, 130/582 (22%) had discordant drug resistance results that potentially led to inadequate 205 treatments in 66/582 (11%) of TB patients (Table 2). In 35/50 (70%) patients, under-diagnosis potentially led to under-treatment, and in 31/80 (39%), over-diagnosis potentially led to over-treatment 206 207 (Table 2). For six patients, we had no treatment information. Of 576 patients with known treatment, we observed that overall, 86/576 (15%) patients received inadequate treatment according to WGS results 208 209 and WHO treatment guidelines: 67/576 (12%) patients were under-treated, and 19 (3%) were overtreated. Consequently, 490/576 (85%) were adequately treated. 210

211 The agreement between local DST and WGS (as assessed by Cohen's kappa) were 0.74 (95% CI 0.69-212 0.8) for pan-susceptible, 0.09 (-0.03-0.2) for mono-resistant, 0.71 (0.65-0.77) for MDR, and 0.49 (0.28-213 0.69) for pre-XDR/XDR-TB cases (Figure 1). Agreement of local DST and WGS for RIF resistance were 0.88 (0.84-0.92) and 0.69 (0.63-0.76) for INH resistance (Figure 1). RIF resistance was, in contrast to 214 215 other drug resistance, more frequently diagnosed with local DST than with WGS (Figure 1). Only three 216 sites tested other drugs than RIF and INH. Two sites tested for SM, two for FQLs, and two for INJ. One 217 site tested for PZA and one site for EMB. Resistance to PAS, CS, EMB, LZD, BDQ, CFZ, and DLM was 218 not tested at any site. Resistance to the latter three was also not diagnosed with WGS using a threshold 219 of \geq 90% variant frequency (Supplementary Table 5).

220 Mortality

We excluded 52/582 (9%) patients due to missing data (<u>Table 1</u>; <u>Supplementary Figure 1</u>). The included patients' median age was 34 years (interquartile range: 27-43 years), 207 (39%) were female, and 218 (41%) were HIV-positive. Based on WGS, the *Mtb* isolates of 310 (58%) patients were pan-susceptible, 32 (6%) mono-resistant, 131 (25%) MDR and 23 (4%) pre-XDR/XDR. Among the 530 isolates, 121 (23%) had a discordant diagnosis. For 30/44 (68%) patients, the under-diagnosis of drug resistance

226 potentially led to under-treatment, and for 28/77 (36%) the over-diagnosis potentially led to over-227 treatment.

228 During treatment, 63/530 (12%) patients died (Table 3). Patients with pan-susceptible Mtb had a mortality of 18/310 (6%), patients with monoresistant TB had a mortality of 6/32 (19%), patients with 229 230 MDR-TB had a mortality of 24/131 (18%), and patients with pre-XDR/XDR-TB had a mortality of 9/23 (39%) (Figure 2A). Overall, mortality ranged from 16/267 (6%) among patients with pan-susceptible 231 232 strains and concordant diagnosis to 7/15 (47%) among patients with pre-XDR/XDR-TB and a discordant 233 diagnosis potentially leading to under-treatment (Table 3). In patients with a discordant diagnosis potentially leading to under-treatment, mortality was 8/30 (27%), and in patients with discordant 234 diagnosis potentially leading to over-treatment, it was 1/28 (4%) (Figure 2B). Mortality ranged from 235 17/293 (6%) in patients with pan-susceptible TB treated according to WHO guidelines to 19/60 (32%) 236 237 in under-treated patients and 1/17 (6%) in patients who were over-treated (Figure 2C).

238 In the multivariable logistic regression adjusted for sex, age, HIV status, history of TB, sputum microscopy, and TB lineage, resistance to any of the anti-TB drugs was associated with higher mortality 239 240 (Figure 3; Supplementary Table 4): the adjusted odds ratio (aOR) was 5.71 (95% CI 3.02-11.25). The 241 association with mortality became stronger with higher degree of drug resistance. Compared to pan-242 susceptible TB, the odds ratios for mono-resistant, MDR-, and pre-XDR/XDR TB were 5.40 (95% CI 243 1.73-15.49), 5.76 (95% CI 2.71-12.54), and 22.07 (95% CI 7.21-68.27), respectively (Figure 3). The 244 aOR for mortality during TB treatment was 3.82 (95% CI 1.47-9.25) in patients with a diagnosis potentially leading to under-treatment, and 0.28 (95% CI 0.02-1.39) in the case of a diagnosis potentially 245 246 leading to over-treatment, compared to patients with concordant treatment (Figure 3). Overall, 77/530 (15%) patients received inadequate treatment based on WGS drug resistance results and WHO 247 guidelines (Supplementary Table 3): 60/530 (11%) patients were under-treated, and 17/530 (3%) were 248 249 over-treated. The odds ratio for mortality for under-treatment was 4.82 (95% CI 2.43-9.44), and for over-250 treatment, it was 0.52 (95% CI 0.03-2.73), compared to patients receiving adequate treatment (Figure 251 <u>3</u>).

The sensitivity analysis using different variant frequency cut-offs (> 0% and 100%) produced similar results (<u>Supplementary Figure 2 and 3</u>). When restricting the analysis to drug resistances which could be diagnosed at sites, again similar results were obtained (Supplementary Figure 4).

be diagnosed at sites, again similar results were obtained (<u>Supplementary Figure 4</u>).

255 Discussion

256

Drug-resistant TB is a significant global health problem. In this multicentre cohort study of 582 TB 257 patients, we compared drug resistance predicted by WGS with the results from local DST in eight high-258 burden TB countries. We examined mortality by drug resistance predicted by WGS, and by 259 260 concordance or discordance with local diagnosis and treatment. We found that the diagnosis was 261 discordant between local drug resistance results and WGS in about one in five patients. The agreement between local and centralized WGS was the highest for RIF and INH but low for other drugs. Of note, 262 263 resistance to SM, PAS, PZA, CS, ETH, EMB, FQLs, and INJ was rarely investigated locally. Mortality 264 during treatment ranged from 6% among patients with pan-susceptible strains and concordant results 265 between WGS and local drug resistance testing to 47% among patients with pre-XDR/XDR TB and 266 discordant results.

To our knowledge, this is the first study to compare the results from DST in real-world settings in highburden countries with WGS and to examine the impact of discordant resistance results on mortality. In a previous study of this cohort, we compared the results from local DST with standardized liquid culture on six drugs performed at the Swiss National Center for Mycobacteria.⁶ In the present study, we used a well-established bioinformatics pipeline and its corresponding database to analyse the WGS data.⁷ The analysis covered 19 drugs, including SM, KM, PZA, ETH, EMB, LFX, and newer drugs. Specifically, we were able to detect more single drug resistance with WGS compared to phenotypic DST.

274 Rapid and accurate diagnosis, prompt and appropriate treatment, and the control of airborne infection are key strategies to prevent drug-resistant TB.²¹ WGS has the potential to predict resistance profiles 275 276 for most anti-TB drugs without the need for time-consuming phenotypic DST.^{1,7,8,16} WGS allows 277 effective individualised treatment and thus reduces the risk of propagating drug resistance. Ineffective 278 treatment may lead to the acquisition of additional drug resistance and increased transmission of drugresistant strains.²¹ These considerations support the use of WGS to replace the current DST methods, 279 280 which cover only a limited number of drugs. Culture-based DST is challenging for several drugs, for 281 example, PZA, ETH, and EMB, due to poor drug solubility.^{8,22} The accurate diagnosis of pertinent drug 282 resistance is essential. For example, PZA is critical to shortening TB therapy, and resistance is related to a worse outcome.²¹ Yet, PZA resistance testing is often unavailable. Only one site could test PZA 283 284 resistance. Routine DST at sites focused mainly on the identification of RIF and INH resistance, used 285 to defined MDR-TB, leaving the efficacy of other drugs unanswered. Furthermore, INH monoresistance 286 would typically be missed when DST relies on the use of Xpert MTB/RIF, which could lead to the under-287 treatment of Xpert-negative individuals. In contrast to other molecular and phenotypic DST methods, 288 WGS simultaneously detects all known drug resistance-conferring mutations. The wider range of drug 289 resistance captured by WGS explains some of the discordant results found in this study. However, 290 discordant results potentially leading to inadequate treatment were mainly due to drug resistance that 291 was undiagnosed, despite the availability of tests at sites, rather than to a wider range of drug 292 resistances captured by WGS.

293 The detection of drug resistance is influenced by the type of sample collected, and the methods used 294 for culturing, DNA extraction and sequencing, and the pipeline used to analyse the sequences.²³ The 295 latter was determined by $a \ge 90\%$ variant frequency cut-off and the robustness of the TBprofiler pipeline 296 and its coverage of all relevant resistance-conferring mutations. Our sensitivity analysis showed that 297 the cut-off for variant frequency had little impact on results. For new drugs, most resistance-conferring 298 mutations are unknown at the time of introduction, and relevant drug resistance mechanisms become 299 apparent only later on. Discrepancies in results between local DST and WGS might be explained by mixed infections, heteroresistance, minority resistant populations, or methodological differences.²³⁻²⁵ 300 and lead to uncertainties in treatment decisions.²⁶ Of note, over-treatment did not increase mortality, 301 302 but the analysis was based on few patients and should be interpreted with caution. Anti-TB drugs can have serious side effects, which may lead to treatment interruption and failure, or acquired drug 303 304 resistance. Over-treatment should be avoided from both a medical and cost perspective.

305 Our study has several limitations. We sampled eligible patients within strata defined by drug resistance 306 and HIV infection and therefore, could not estimate the incidence or prevalence of drug-resistant TB in 307 HIV-positive or HIV-negative patients. We could also not evaluate differences in drug resistance 308 between Mtb lineages, because the sample size was small for several lineages. Further, we sequenced 309 Mtb strains before treatment and could thus not diagnose potential acquired drug resistance, which may 310 influence treatment outcome. Finally, we started this study in 2013. Since then, TB treatment guidelines changed. In 2013, WHO published an interim policy guideline on BDQ and in 2014 on DLM in the 311 treatment of MDR-TB.^{27,28} In our study, patients were rarely treated with new drugs. Consequently, our 312 results may not reflect the situation in 2020. However, our study does show that treatment strategies 313 314 guided by comprehensive drug resistance data are likely to save lives.

315 Our results support WHO's call for an accurate point-of-care test based on WGS that can be performed directly from sputum samples.²⁹ Such tests would allow rapid diagnosis and efficient, individual-based 316 treatment of drug-resistant TB. Test systems performing WGS on sputum samples and bioinformatics 317 318 pipelines are currently in development. High-burden countries should consider building central, high-319 throughput sequencing capacities. The establishment of a trustworthy, widely accepted drug resistance 320 database similar to the Stanford HIV drug resistance database will be essential in this context.³⁰ Finally, 321 we support the call for clinical trials evaluating the efficacy, safety, tolerability of new TB treatment and 322 DST strategies for drug-resistant TB.²¹ Especially, the role of new drugs like BDQ, DLM, and pretomanid 323 in regimens with fewer, more effective and safer drugs needs to be evaluated.²¹ Future studies should 324 also examine treatment duration and adherence.²¹ The duration of the intensive and continuation 325 phases of TB treatment and treatment adherence are crucial for efficient therapy.

In conclusion, our study shows that both the accuracy of DST in routine care and the access to testing for resistance for several essential drugs is limited in high-burden TB countries and that this leads to inadequate treatment and contributes to higher mortality. Our results support the role of WGS to improve the management of drug-resistant TB in high-burden TB settings.

Data availability 330

331 WGS data from patients Mtb strains included in this analysis have been submitted to the NCBI 332 (PRJNA300846; Supplementary Table 6).

Acknowledgement 333

334 We thank all sites that participated, patients whose data were used in this study. We are also grateful 335 to the Tuberculosis Working Group of IeDEA for helpful discussions. This research was supported by the Swiss National Foundation (project grant numbers 153442, 310030 188888, IZRJZ3 164171, 336 337 IZLSZ3 170834, CRSII5 177163 and special project grant 17481). The International Epidemiology 338 Databases to Evaluate AIDS (IeDEA) is supported by the US National Institutes of Health, National 339 Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child 340 Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, 341 the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute 342 on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney Diseases, the Fogarty International Center, and the National Library of Medicine: Asia-Pacific, 343 344 U01AI069907; CCASAnet, U01AI069923; Central Africa, U01AI096299; East Africa, U01AI069911; NA-ACCORD, U01Al069918; Southern Africa, U01Al069924; West Africa, U01Al069919. RJW 345 receives support from the Francis Crick Institute, which is funded by UKRI, CRUK (FC0010218), and 346 347 Wellcome (104803, 203135). This work is solely the responsibility of the authors and does not necessarily represent the official views of any of the institutions mentioned above. Calculations were 348 349 performed on UBELIX (http://www.id.unibe.ch/hpc), the HPC cluster at the University of Bern.

References 351

352 1. WHO. Global tuberculosis report 2019. World Health Organization Document 2019: 1-297.

353 2. Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies 354 of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. 355 AIDS 2015.

356 3. Mesfin YM, Hailemariam D, Biadgilign S, Kibret KT. Association between HIV/AIDS and multi-357 drug resistance tuberculosis: a systematic review and meta-analysis. PloS one 2014; 9(1): e82235.

Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant 358 4. 359 tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375(9728): 1830-43.

360 5. Antiretroviral Therapy in Low-Income Countries Collaboration of the International epidemiological Databases to Evaluate A, Collaboration ARTC, Brinkhof MW, et al. Tuberculosis after 361 362 initiation of antiretroviral therapy in low-income and high-income countries. *Clin Infect Dis* 2007; **45**(11): 363 1518-21.

364 6. Zürcher K, Ballif M, Fenner L, et al. Drug susceptibility testing and mortality in patients treated 365 for tuberculosis in high-burden countries: a multicentre cohort study. The Lancet Infectious Diseases 2019; 19(3): 298-307. 366

367 7. Phelan JE, O'Sullivan DM, Machado D, et al. Integrating informatics tools and portable 368 sequencing technology for rapid detection of resistance to anti-tuberculous drugs. Genome Med 2019; 369 **11**(1): 41.

370 8. Gygli SM, Keller PM, Ballif M, et al. Whole-Genome Sequencing for Drug Resistance Profile 371 Prediction in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2019; 63(4).

372 Consortium CR, the GP, Allix-Beguec C, et al. Prediction of Susceptibility to First-Line 9. 373 Tuberculosis Drugs by DNA Sequencing. N Engl J Med 2018; 379(15): 1403-15.

374 van Embden JD, Cave MD, Crawford JT, et al. Strain identification of Mycobacterium 10. 375 tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 376 1993; **31**(2): 406-9.

377 Coll F, Phelan J, Hill-Cawthorne GA, et al. Genome-wide analysis of multi- and extensively 11. drug-resistant Mycobacterium tuberculosis. Nat Genet 2018; 50(2): 307-16. 378

379 Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis 12. from the complete genome sequence. Nature 1998; 393(6685): 537-44. 380

381 13. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods 2012; 9(4): 382 357-9.

383 14. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. 384 Bioinformatics 2009; 25(14): 1754-60.

385 15. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and SAMtools. 386 Bioinformatics 2009; 25(16): 2078-9.

Coll F, McNerney R, Preston MD, et al. Rapid determination of anti-tuberculosis drug resistance 387 16. 388 from whole-genome sequences. Genome Med 2015; 7(1): 51.

WHO. Consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health
 Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.

Team RC. R: A language and environment for statistical computing. In: Computing RFfS, editor.
 Vienna, Austria 2019.

393 19. Cohen J. A Coefficient of Agreement for Nominal Scales. *Educational and Psychological* 394 *Measurement* 2016; **20**(1): 37-46.

395 20. Team PC. Python: A dynamic, open source programming language. Python Software396 Foundation; 2019.

Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official
 ATS/CDC/ERS/IDSA Clinical Practice Guideline. *Am J Respir Crit Care Med* 2019; **200**(10): e93-e142.

399 22. Dominguez J, Boettger EC, Cirillo D, et al. Clinical implications of molecular drug resistance
 400 testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. *Int J Tuberc Lung* 401 *Dis* 2016; **20**(1): 24-42.

402 23. Metcalfe JZ, Streicher E, Theron G, et al. Mycobacterium tuberculosis Subculture Results in
403 Loss of Potentially Clinically Relevant Heteroresistance. *Antimicrob Agents Chemother* 2017; 61(11).

Cohen T, van Helden PD, Wilson D, et al. Mixed-strain mycobacterium tuberculosis infections
and the implications for tuberculosis treatment and control. *Clin Microbiol Rev* 2012; **25**(4): 708-19.

406 25. Streicher EM, Bergval I, Dheda K, et al. Mycobacterium tuberculosis population structure
407 determines the outcome of genetics-based second-line drug resistance testing. *Antimicrob Agents*408 *Chemother* 2012; **56**(5): 2420-7.

409 26. Hofmann-Thiel S, Hoffmann H, Hillemann D, Rigouts L, Van Deun A, Kranzer K. How should
410 discordance between molecular and growth-based assays for rifampicin resistance be investigated? *Int*411 *J Tuberc Lung Dis* 2017; **21**(7): 721-6.

412 27. WHO. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: Interim policy
413 guidance. Geneva: World Health Organization; 2013. (WHO/HTM/TB/2013.6).

414 28. WHO. The use of delamanid in the treatment of multidrug-resistant tuberculosis. Geneva: World
415 Health Organization; 2014 (WHO/HTM/TB2014.23).

WHO. The use of next-generation sequencing technologies for the detection of mutations
associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. Geneva:
World Health Organization; 2018 (WHO/CDS/TB/2018.19). Licence: CC BY-NCSA 3.0 IGO.

30. Shafer RW. Rationale and uses of a public HIV drug-resistance database. *J Infect Dis* 2006; **194 Suppl 1**: S51-8.

Factor	Pan- susceptible	Any resistance	p- value*	Mono- resistance	INH	PZA	EMB	RIF	Poly- resistance	MDR	pre-/XDR	others
	339	243	≤0.0001	35	8	2	1	24	208	146	24	38
Gender												
Women	131 (39%)	94 (39%)	≤0.05	10 (29%)	3 (38%)	0 (0%)	1 (100%)	6 (25%)	84 (40%)	56 (38%)	13 (54%)	15 (39%)
Men	208 (61%)	149 (61%)	≤0.01	25 (71%)	5 (62%)	2 (100%)	0 (0%)	18 (75%)	124 (60%)	90 (62%)	11 (46%)	23 (61%)
Age												
At diagnosis (IQR)	35 [28, 45]	32 [25, 40]	0.75	32 [25, 40]	40 [31.25, 48.5]	26 [24.5, 27.5]	36 [36, 36]	29 [24.75, 38.5]	32 [25.75, 40.25]	31 [25, 39]	29.5 [24.75, 34.25]	36 [29.2 43.75]
HIV status												
HIV-negative	169 (50%)	166 (68%)	0.87	23 (66%)	7 (88%)	1 (50%)	0 (0%)	15 (62%)	143 (69%)	103 (71%)	14 (58%)	26 (68%
HIV-positive	170 (50%)	77 (32%)	≤0.0001	12 (34%)	1 (12%)	1 (50%)	1 (100%)	9 (38%)	65 (31%)	43 (29%)	10 (42%)	12 (32%
Mtb Lineage												
L1	18 (5%)	6 (2%)	≤0.05	2 (6%)	0 (0%)	0 (0%)	0 (0%)	2 (8%)	4 (2%)	1 (1%)	0 (0%)	3 (1%)
L2	79 (23%)	56 (17%)	≤0.05	7 (20%)	3 (38%)	1 (50%)	0 (0%)	3 (12%)	49 (13%)	23 (16%)	8 (Inf%)	18 (47%
L3	15 (4%)	3 (1%)	≤0.01	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (1%)	2 (1%)	1 (4%)	0 (0%)
L4	225 (66%)	178 (66%)	≤0.05	26 (74%)	5 (62%)	1 (50%)	1 (100%)	19 (79%)	152 (73%)	120 (82%)	15 (62%)	17 (45%)
L5	1 (<1%)	0 (0%)	0.32	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
L6	1 (<1%)	0 (0%)	0.32	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Country												
Côte d'Ivoire	46 (14%)	48 (20%)	0.84	5 (14%)	2 (25%)	0 (0%)	1 (100%)	2 (8%)	43 (21%)	39 (27%)	3 (12%)	1 (3%)
Democratic Republic of the Congo	29 (9%)	30 (12%)	0.9	1 (3%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)	29 (14%)	19 (13%)	8 (33%)	2 (5%)
Kenya	21 (6%)	7 (6%)	≤0.01	1 (3%)	1 (12%)	0 (0%)	0 (0%)	0 (0%)	6 (3%)	5 (3%)	0 (0%)	1 (3%)
Nigeria	19 (6%)	34 (14%)	≤0.05	6 (0%)	0 (0%)	0 (0%)	0 (0%)	6 (25%)	28 (13%)	20 (14%)	4 (17%)	4 (11%)
South Africa	111 (33%)	61 (25%)	≤0.001	15 (43%)	0 (0%)	1 (50%)	0 (0%)	14 (58%)	46 (22%)	28 (19%)	7 (29%)	11 (29%
Peru	57 (17%)	36 (15%)	≤0.05	2 (6%)	2 (25%)	0 (0%)	0 (0%)	0 (0%)	34 (16%)	28 (19%)	2 (8%)	4 (11%)
Thailand	56 (17%)	27 (116%)	≤0.01	5 (14%)	3 (38%)	1 (50%)	0 (0%)	1 (4%)	22 (11%)	7 (5%)	0 (0%)	15 (39%
History of TB												
No	269 (79%)	104 (43%)	≤0.0001	13 (37%)	7 (88%)	1 (50%)	1 (100%)	4 (17%)	91 (44%)	56 (38%)	5 (21%)	30 (79%

422 Table 1. Patient characteristics by resistance profiles obtained by whole-genome sequencing.

Yes	70 (21%)	139 (79%)	≤0.0001	22 (63%)	1 (12%)	1 (50%)	0 (0%)	20 (83%)	117 (56%)	90 (62%)	19 (79%)	8 (21%)
Treatment success												
Cured	189 (56%)	83 (78%)	≤0.0001	10 (29%)	3 (38%)	0 (0%)	1 (100%)	6 (25%)	73 (35%)	45 (31%)	8 (33%)	20 (53%)
Completed	59 (17%)	46 (19%)	0.2	6 (17%)	2 (25%)	0 (0%)	0 (0%)	4 (17%)	40 (19%)	31 (21%)	3 (12%)	6 (16%)
Died	19 (6%)	45 (19%)	≤0.01	6 (17%)	1 (12%)	1 (50%)	0 (0%)	4 (17%)	39 (19%)	24 (16%)	9 (38%)	6 (16%)
Treatment failure	11 (3%)	10 (4%)	0.83	3 (9%)	0 (0%)	1 (50%)	0 (0%)	2 (8%)	7 (3%)	5 (3%)	2 (8%)	0 (0%)
Defaulted	20 (6%)	22 (9%)	0.76	0 (9%)	0 (0%)	0 (0%)	0 (0%)	3 (12%)	19 (9%)	17 (12%)	0 (0%)	2 (5%)
Lost to follow up	6 (2%)	7 (3%)	0.78	2 (6%)	0 (0%)	0 (0%)	0 (0%)	2 (8%)	5 (2%)	5 (3%)	0 (0%)	0 (0%)
Ongoing, unknown	22 (6%)	15 (6%)	0.25	3 (97%)	2 (25%)	0 (0%)	0 (0%)	1 (4%)	12 (6%)	9 (6%)	0 (0%)	3 (8%)
Sputum												
Positive	264 (80%)	205 (85%)	≤0.01	25 (71%)	7 (88%)	1 (50%)	1 (100%)	16 (67%)	180 (87%)	129 (88%)	17 (74%)	34 (92%)
Negative	68 (20%)	36 (15%)	≤0.01	10 (29%)	1 (12%)	1 (50%)	0 (0%)	8 (33%)	26 (13%)	17 (12%)	6 (26%)	3 (8%)

P-value*, difference between pan-susceptible and any resistance with chi-square test. The category others includes following drug resistance: CS; EMB,RIF;
ETH; INH,ETH; INH,PZA; PAS,INH,OFX,CIP,MFX,LFX; SM; SM,EMB; SM,EMB,RIF,OFX,CIP,MFX,LFX; SM,INH; SM,INH,EMB; SM,INH,ETH;
SM,PZA,ETH,RIF. Abbreviations: IQR, interquartile range; *Mtb*, *Mycobacterium tuberculosis*; MDR, multi-drug-resistant; pre-XDR/XDR, pre-/ extensively-drugresistant; WGS, whole-genome sequencing; SM, streptomycin; PAS, para-aminosalicylic-acid; INH, isoniazid; PZA, pyrazinamide, CS, cycloserine; ETH,
ethionamide; EMB, ethambutol; RIF, rifampicin; OFX, ofloxacin; CIP, ciprofloxacin; MFX moxifloxacin; LFX, levofloxacin.

431 Table 2: Drug resistance results from whole-genome sequencing and local testing by diagnosis concordance and consequences for treatment.

	Drug resistance categories ba	sed on:	Diagnosis method	Diagnosis method:						
	Diagnosis with WGS	Diagnosis at sites	Xpert MTB/RIF*	Culture	LPA	Combination of tests				
Concordant diagnosis										
Total: 452 (100%)			242 (100%)	195 (100%)	60 (100%)	102 (100%)				
293 (65%)	Pan-susceptible	Pan-susceptible	196 (81%)	139 (71%)	49 (82%)	53 (52%)				
5 (1%)	Monoresistance: 3 INH 2 RIF	Monoresistance: 3 INH 2 RIF	0 (0%)	4 (2%)	1 (1.67%)	0 (0%)				
138 (31%)	MDR	MDR	45 (18.6%)	44 (23%)	8 (13%)	44 (43%)				
9 (2%)	pre-XDR/XDR	pre-XDR/XDR	1 (<1%)	1 (<1%)	2 (3%)	5 (5%)				
7 (2%)	Others: 7 SM.	Others: 7 SM	0 (0%)	7 (4%)	0 (0%)	0 (0%)				
Discordant diagnosis										
Total: 130 (100%)			35 (100%)	55 (100%)	9 (100%)	46 (100%)				
Potentially leading to under-treatment										
Total: 35 (100%)			17 (100%)	12 (100%)	1 (100%)	5 (100%)				
0 (0%)	Pan-susceptible	-	0 (0%)	0 (0%)	0 (0%)	0 (0%)				
3 (9%)	Monoresistance: 3 INH	3 Pan-susceptible	2 (12%)	1 (8%)	0 (0%)	0 (0%)				
5 (14%)	MDR	3 Pan-susceptible 1 RIF 1 SM;EMB	2 (12%)	1 (8%)	1 (100%)	1 (20%)				
15 (43%)	pre-XDR/XDR	MDR	5 (29%)	6 (50%)	0 (0%)	4 (80%)				
12 (34%)	Others: 10 INH;ETH 1 SM;INH;ETH 1 SM;INH	Pan-susceptible Pan-susceptible Pan-susceptible	8 (47%)	4 (33%)	0 (0%)	0 (0%)				
Potentially leading										
to over-treatment Total: 31 (100%)			3 (100%)	12 (100%)	2 (100%)	14 (50%)				
23 (74%)	Pan-susceptible	1 INH 18 MDR 4 RIF	3 (100%)	9 (75%)	2 (100%)	9 (64%)				
2 (6%)	Monoresistance: 2 INH	MDR	0 (0%)	2 (16.67%)	0 (0%)	0 (0%)				

3 (10%)	MDR	pre-XDR/XDR	0 (0%)	0 (0%)	0 (0%)	3 (21%)
0 (0%)	pre-XDR/XDR	-	0 (0%)	0 (0%)	0 (0%)	0 (0%)
3 (10%)	Others: 1 INH;PZA 1 SM;INH;EMB 1 INH;ETH	MDR MDR MDR	0 (0%)	1 (8%)	0 (0%)	2 (14%)
Other discordance in diagnosis						
Total: 64 (100%)			15 (100%)	31 (100%)	6 (100%)	27 (100%)
23 (36%)	Pan-susceptible	20 EMB 1 Monoresistance* 1 SM	2 (13%)	20 (65%)	0 (0%)	1 (4%)
25 (39%)	Monoresistance: 20 RIF 2 PZA 1 EMB	MDR Pan-susceptible Pan-susceptible	6 (40%)	1 (3%)	1 (17%)	20 (74%)
0 (0%)	MDR	-	0 (0%)	0 (0%)	0 (0%)	0 (0%)
0 (0%)	pre-XDR/XDR	-	0 (0%)	0 (0%)	0 (0%)	0 (0%)
16 (25%)	Others: 5 ETH 1 CS. 1 SM. 3 INH;ETH 1 SM;EMB;RIF;OFX;CIP;MFX;LFX 1 SM. 1 PAS;INH;OFX;CIP;MFX;LFX 1 SM;PZA;ETH;RIF 1 EMB;RIF	Pan-susceptible Pan-susceptible SM;EMB INH SM MDR Pan-susceptible INH MDR MDR	7 (47%)	10 (32%)		6 (22%)

Abbreviations: vs, versus; WGS, whole-genome sequencing; *Mtb*, Mycobacterium tuberculosis; DST, drug susceptibility test; LPA, line probe assay; MDR,
multi-drug-resistant; pre-XDR/XDR, pre-/extensively drug-resistant; WHO, World Health Organization; SM, streptomycin; PAS, para-aminosalicylic-acid; INH,
isoniazid; PZA, pyrazinamide; CS, cycloserine; ETH, ethionamide; EMB, ethambutol; RIF rifampicin; OFX, ofloxacin; CIP, ciprofloxacin; MFX moxifloxacin; LFX,
levofloxacin. *exact Monoresistance is not known; *RIF resistance diagnosed with Xpert MTB/RIF was classified as MDR.


	Total	Concordant with diagnosis at sites	Discordant with diagnosis at sites						
			Any discordance	Potentially leading to under-treatment	Potentially leading to over-treatment	Other discordance			
Resistance based on WGS:	63/530 (12%)	44/409 (11%)	19/121 (16%)	8/30 (27%)	1/28 (4%)	10/63 (16%)			
Pan-susceptible	18/310 (6%)	16/267 (6%)	2/43 (5%)	0/0	0/20 (0%)	2/23 (9%)			
Any resistance	45/220 (20%)	28/142 (20%)	17/78 (22%)	8/30 (27%)	1/8 (12%)	8/40 (20%)			
Mono-resistance:	6/32 (19%)	2/4 (50%)	4/28 (14%)	0/1 (0%)	0/2 (0%)	4/25 (16%)			
INH	1/6 (17%)	1/3 (33%)	0/3 (0%)	0/1 (0%)	0/2 (0%)	0/0			
PZA	1/2 (50%)	0/0	1/2 (50%)	0/0	0/0	1/2 (50%)			
EMB	0/1 (0%)	0/0	0/1 (0%)	0/0	0/0	0/1 (0%)			
RIF	4/23 (17%)	1/1 (100%)	3/22 (14%)	0/0	0/0	3/22 (14%)			
Poly-resistance:	39/188 (21%)	26/138 (19%)	13/50 (26%)	8/29 (28%)	1/6 (17%)	4/15 (27%)			
MDR	24/131 (18%)	23/123 (19%)	1/8 (12%)	1/5 (20%)	0/3 (0%)	0/0			
pre-XDR/XDR	9/23 (39%)	2/8 (25%)	7/15 (47%)	7/15 (47%)	0/0	0/0			
Others	6/34 (18%)	1/7 (14%)	5/27 (19%)	0/9 (0%)	1/3 (33%)	4/15 (27%)			

440 Table 3: Mortality by concordance of local diagnosis and whole-genome sequencing.

441

Analysis based on 530 patients with complete data. The estimated mortality is calculated by comparing the deaths compared to the total of the category.
Abbreviations: WGS, whole-genome sequencing; MDR, multi-drug-resistant; pre-XDR/XDR, pre-/extensively drug-resistant; Others: CS; EMB,RIF; ETH;
INH,ETH; INH,PZA; PAS,INH,OFX,CIP,MFX,LFX; SM; SM,EMB; SM,EMB,RIF,OFX,CIP,MFX,LFX; SM,INH; SM,INH,EMB; SM,INH,ETH; SM,PZA,ETH,RIF;
SM, streptomycin; PAS, para-aminosalicylic-acid; INH, isoniazid; PZA, pyrazinamide, CS cycloserine; ETH, ethionamide; EMB, ethambutol; RIF, rifampicin;


446 OFX, ofloxacin; CIP, ciprofloxacin; MFX, moxifloxacin; LFX, levofloxacin.



448

Figure 1. Distribution of diagnosed drug resistance between whole-genome sequencing and 449 450 local DST. The categories include pan-susceptible TB, monoresistant TB (any monoresistance), MDR-TB, pre-XDR/XDR-TB, any INH-resistant TB, any RIF-resistant TB. Abbreviations: WGS, whole-451 452 genome sequencing; DST, drug susceptibility testing; MDR, multi-drug-resistant; pre-XDR/XDR, pre-453 /extensively drug-resistant; INH, isoniazid; RIF rifampicin.








455 Figure 2. Mortality according to drug resistance, concordance of diagnosis, and treatment adequacy (according to WHO guidelines, see also supplementary tables 1 and 2). Error bars are 456 457 standard errors. Analysis based on 530 patients with complete data. The estimated mortality is 458 calculated by comparing the deaths compared to the total amount of the category. Abbreviations: WHO,

- 459 World Health Organization; MDR, multi-drug-resistant; pre-XDR/XDR, pre-extensively and extensively
- 460 drug-resistant.



Categories	Factors	N= 530				OR (95%-CI)
Drug resistance compared to pan-susceptible	Any resistance	220			⊢ ⊢	4.17 (2.38-7.6) 5.71 (3.02-11.25)
Drug resistance compared to pan-susceptible	Monoresistance	32				3.74 (1.27-9.83) 5.4 (1.73-15.49)
	MDR	131			⊧ <u></u> i	3.64 (1.91-7.06) 5.76 (2.71-12.54)
	pre-XDR/XDR	23			⊢; ⊢;	10.43 (3.89-27.27) 22.07 (7.21-68.27)
	Other drug resistance	34			⊧; ⊨t	3.48 (1.18-9.07) 3.52 (1.12-9.95)
Discordant diagnosis compared to concordant diagnosis	Potentially leading to under-treatment	30			 	3.02 (1.2-6.95) 3.82 (1.47-9.25)
	Potentially leading to over-treatment	28				0.31 (0.02-1.5) 0.28 (0.02-1.39)
	Other discordances	63		F		1.57 (0.71-3.19) 1.64 (0.73-3.42)
Inadequate treatment compared to adequate treatment	Under-treatment	60				4.42 (2.33-8.22) 4.82 (2.43-9.44)
	Over-treatment	17				0.6 (0.03-3.03) 0.52 (0.03-2.73)
		0.01		1 1 Outcome:	1 : mortality	100

461

Figure 3. Results from four logistic regression models (adjusted for sex, age, HIV status, history of TB, sputum microscopy, and TB lineage) to assess 1) the impact of any drug resistance on mortality, 2) the impact of drug resistance categories on mortality, 3) the impact of diagnosis discordance on mortality, 4) the impact of treatment adequacy (according to WHO guidelines) on mortality. Abbreviations: OR, odds ratio; CI, confidence interval; N, number; *Mtb*, *Mycobacterium tuberculosis*; WHO, world health organisation; MDR, multi-drug-resistant; pre-XDR/XDR, pre-extensively and extensively drug-resistant.